高强度聚焦超声消融联合药物基因组学指导化疗治疗晚期胰腺癌的初步经验
本研究纳入31例不可切除胰腺癌患者(III期17例、IV期14例),分为HIFU后药物基因组学指导化疗组(A组13例)与HIFU后传统化疗组(B组18例)。结果显示A组疼痛缓解持续时间、中位生存时间及6、12个月生存率均优于B组,两组无灌注体积比无显著差异,HIFU相关无≥3级严重并发症。
要点
- HIFU可有效缓解晚期胰腺癌疼痛,18例患者疼痛评分从术前6.6±2.2降至术后3.3±1.0(p=0.000)。
- A组疼痛缓解持续时间5.2±3.2个月,优于B组2.4±1.3个月(p=0.026)。
- A组中位生存14个月、6和12个月生存率74.1%和59.3%,均优于B组(5个月、32.4%和19.4%,p=0.04)。
核心结论
- HIFU联合药物基因组学指导化疗治疗晚期胰腺癌安全有效,在疼痛缓解、生活质量和生存获益方面优于HIFU联合传统化疗,该联合方案可能成为晚期胰腺癌治疗的重要补充。
研究设计与样本
- 单臂分组初步经验研究,纳入31例不可切除胰腺癌患者(III期17例、IV期14例),A组13例接受HIFU后药物基因组学指导化疗,B组18例接受HIFU后传统化疗;采用增强CT和MRI评估肿瘤反应,数值评定量表评估疼痛,Kaplan-Meier法和log-rank检验分析生存。
关键影像表现/征象
- 18例患者HIFU术后疼痛强度评分较术前下降(6.6±2.2降至3.3±1.0,p=0.000)。
- A组无灌注体积比83.5%±22.3%,B组85.3%±16.8%,两组间无显著差异。
诊断标准与关键数值
- A组疼痛缓解持续时间5.2±3.2个月,B组2.4±1.3个月(p=0.026)。
- A组中位生存时间14个月,B组5个月;A组6个月和12个月生存率分别为74.1%和59.3%,B组分别为32.4%和19.4%,两组生存差异显著(p=0.04)。
- A组3级骨髓抑制2例(15.4%),B组7例(38.9%);HIFU相关无≥3级严重并发症。
临床应用与阅片要点
- HIFU联合药物基因组学指导化疗可能为晚期胰腺癌患者带来疼痛缓解和生存获益,作者认为该联合方案可能成为晚期胰腺癌治疗的重要补充。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the safety and efficacy of high-intensity focused ultrasound (HIFU) ablation combined with pharmacogenomic-guided chemotherapy in treating patients with advanced pancreatic cancer (PC).
METHODS: Thirty-one patients with unresectable PC (stage III 17, stage IV 14) were enrolled in this study. The patients were divided into group A (pharmacogenomic-guided chemotherapy following HIFU treatment, n = 13) and group B (traditional chemotherapy following HIFU treatment, n = 18). Contrast-enhanced computed tomography and magnetic resonance imaging were used to evaluate tumor response. Pain intensity was assessed using the numerical rating scale. The Kaplan-Meier method and log-rank test were used to analyze survival.
RESULTS: The mean pain intensity score in 18 patients decreased from 6.6 ± 2.2 before HIFU to 3.3 ± 1.0 after HIFU (p = 0.000). The mean duration of pain relief was 5.2 ± 3.2 mo in group A and 2.4 ± 1.3 mo in group B (p = 0.026). There was no significant difference of the non-perfused volume ratio (83.5% ± 22.3% in group A and 85.3% ± 16.8% in group B) between the two groups. The median survival time was 14 mo in group A and 5 mo in group B. The 6 and 12-mo survival rates were 74.1% and 59.3% in group A, and 32.4% and 19.4% in group B, respectively. The difference in survival between the two groups was significant (p = 0.04). No severe complications (≥grade 3) related to HIFU were observed. Bone marrow depression was the main adverse reaction related to chemotherapy, with grade 3 bone marrow depression observed 2 (15.4%) patients in group A and 7 (38.9%) patients in group B.
CONCLUSION: HIFU combined with pharmacogenomic-guided chemotherapy is safe and effective in treating patients with advanced PC. It provides better clinical outcomes in pain relief, quality of life and survival benefits for patients with advanced PC compared to HIFU combined with traditional chemotherapy. This combined approach may have the potential to become an important supplement to the treatment of advanced PC.
引用
- Ran L, Yang W, Chen X, et al. High-Intensity Focused Ultrasound Ablation Combined With Pharmacogenomic-Guided Chemotherapy for Advanced Pancreatic Cancer: Initial Experience. Ultrasound Med Biol. 2024. PMID: 39025741. doi:10.1016/j.ultrasmedbio.2024.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。